Q2 2026
Company Update
Mesoblast's FDA-approved cell therapy RYONCIL crossed $100 million in cumulative net revenue since launch, with Q3 generating $30.3 million in net sales as the company pivots to profitable growth. Net operating cash burn compressed to just $4.1 million last quarter while the company banked a fresh $125 million term loan, fueling a deep pipeline including a Phase 3 chronic low back pain trial poised to read out mid-2027.
